Salix Pharmaceuticals


Analysts Reiterate Bullish Stance on Valeant Pharmaceuticals Intl as it Wins Takeover Fight for Salix

By Sarah Roden Valeant Pharmaceuticals (NYSE:VRX) beat out Endo International in a battle to take over Salix Pharmaceuticals (NASDAQ:SLXP) in a deal valued …

Looking Ahead of Wall Street: Salix Pharmaceuticals, Receptos, Tetraphase

A handful of bio-pharmaceutical stocks are announcing their financial results for the final quarter of 2014 this week. What should investors watch for?

Company Update (NASDAQ:SLXP): Valeant to Acquire Salix Pharmaceuticals for $158.00 Per Share in Cash

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced that they have entered into a definitive agreement under which Valeant will acquire all …

SLXP: Salix Announces the Promotion of William P. Forbes, PharmD to President, Medical, R&D and Chief Development Officer

(BUSINESS WIRE)–Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) (“Salix” or the “Company”) today announced the promotion of William P.

SLXP: Pharming and Salix Announce First Patient Treated in Clinical Study of Ruconest® for Prophylaxis of Hereditary Angioedema

(BUSINESS WIRE)–Pharming Group NV (EURONEXT: PHARM) and Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the first patient was treated in their Phase 2 …

Cantor Cuts Salix Pharmaceuticals Price Target On Inventory Disclosure

In a research report issued today, Cantor analyst Irina Rivkind reiterated a Buy rating on Salix Pharmaceuticals (NASDAQ:SLXP), but reduced her price target to $127 …

Roth Capital Moves To The Sideline On Salix Pharmaceuticals; Cuts PT To $95

In a research report issued today, Roth Capital analyst Scott Henry downgrades shares of Salix Pharmaceuticals (NASDAQ:SLXP) from Buy to Hold and reduced his price …

Salix: Containing Our Frustration – Seeing Steep Selloff As A Bit Overdone, Says Brean Capital

In a research report released today, Brean Capital analyst Jonathan Aschoff reaffirmed a Buy rating on Salix Pharmaceuticals (NASDAQ:SLXP) with a price target …

William Blair Maintains Outperform On Salix Following Cosmo Deal Cancellation

In a research report issued today, William Blair analyst Tim Lugo maintained an Outperform rating on Salix Pharmaceuticals (NASDAQ:SLXP) with a $184 price target, following today’s …

Cantor Fitzgerald Reiterates Buy On Salix Pharma, Increases PT To $181

In a research report published today, Cantor Fitzgerald analyst Irina Rivkind reiterated her Buy rating on Salix Pharma (NASDAQ:SLXP) and increased her price …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts